Definium Therapeutics, Inc.
Nasdaq · Medicinal Chemicals & Botanical Products
Company Overview
A concise company profile alongside the latest public filing activity.
Definium Therapeutics is a biopharmaceutical company that develops small-molecule and other drug candidates targeting central nervous system and other medical conditions, advancing them through preclinical and clinical research toward regulatory approval.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Barrow RobertChief Executive Officer | Sell | $722K | 19,023at $37.94 | Sep 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable DFTX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.